Stock Screener App

Frei - Play StoreApp Store

Installieren Installieren

Dow:

Nasdaq:

S&P 500:

BMY

$62.481.78%1.09

Nachbörslich: 62.55+0.07 +0.11%

Bristol Myers Squibb Co (BMY)

Date: O: H: L: C: Vol:

Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten

BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress - Zacks Investment Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research

BofA raises Bristol-Myers Squibb stock price target to $67 - Investing.com

How Bristol Myers’s CEO Challenged the Company’s Managers - WSJ

Is Bristol-Myers Squibb (BMY) Stock Cheap, Or Are Risks Priced In? - Simply Wall St

Wells Fargo cuts Bristol-Myers Squibb stock price target on LOE concerns - Investing.com Canada

Truist reiterates Buy on Bristol-Myers Squibb stock on Q3 beat By Investing.com - Investing.com Canada

Bristol-Myers Squibb Co. (BMY) PT Lowered to $60 at Wells Fargo - StreetInsider

Company News for Oct 30, 2026 - Zacks Investment Research

2027 Could Finally Be the Year Cancer Is on the Ropes! - GlobeNewswire Inc.

Bristol-Myers Squibb Company (BMY) Seasonal returns chart - Yahoo Finance Australia

Bristol-Myers Squibb Company (BMY) Seasonal returns chart - Yahoo Finance Singapore

Bristol-Myers Squibb Co (BRM.HM) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

Bristol-Myers Squibb Company (BMY) Seasonal returns chart - Yahoo Finance UK

Bristol-Myers Squibb Company (BMY) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

BMS Aims To Build Confidence In Pipeline As Growth Portfolio Sees Gains - Scrip

Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch

Bristol-Myers Squibb Co (BMY) (Q3 2026) Earnings Call Highlights - GuruFocus

Bristol Myers’ Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction - The Motley Fool

What's Going On With Bristol-Myers Squibb Stock Thursday? - Bristol-Myers Squibb (NYSE:BMY) - Benzinga

BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook - Zacks Investment Research

Bristol Myers Squibb beats forecasts and nudges up sales outlook - MedWatch

Bristol Myers Raises Sales Guidance on Demand For New Drugs - Bloomberg.com

Bristol Myers lifts sales outlook as newer medicines grow - The Pharma Letter

Bristol-Myers Squibb Q3 2026 Earnings Call Transcript - Benzinga

Bristol Myers Squibb (BMY) Raises 2026 Revenue Outlook After Str - GuruFocus

Bristol-Myers Squibb Reports Q3 2026 Revenue of $13.1 Billion an - GuruFocus

BRISTOL-MYERS SQUIBB ($BMY) Releases Q3 2026 Earnings - Quiver Quantitative

Bristol Myers Squibb Reports Third Quarter Financial Results for 2026 - Finviz

Form 8-K BRISTOL MYERS SQUIBB CO For: Oct 29 - StreetInsider

Bristol Myers: Q3 Earnings Snapshot - Yahoo Finance

Bristol Myers: Q3 Earnings Snapshot - kare11.com

86,136 Bristol Myers Squibb Company $BMY Shares Sold by Conning Inc. - MarketBeat

Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight - GlobeNewswire Inc.

Bristol-Myers Squibb earnings loom as pipeline takes center stage - Investing.com

Pathos raises $237M and lands Alzheimer’s drug deal with Tempus, Bristol Myers - Crain's Chicago Business

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? - The Motley Fool

What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings? - Zacks Investment Research

What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings? - TradingView

AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy? - Zacks Investment Research

Bristol Myers Squibb’s Cancer Drug Just Doubled Survival Time Without Progression — Here’s Why It Matters - The Motley Fool

3 Cheap Dividend Stocks I'd Buy Without Any Hesitation - The Motley Fool

Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings? - Zacks Investment Research

Bristol-Myers Squibb (NYSE:BMY): Weighing Dividend Quality for Income Investors - ChartMill

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study - BioSpace

Bristol Myers Iza-Bren Phase 3 PFS Reaches 11.1 Months - grafa.com

Breakfast News: Science Strikes Back at Cancer - The Motley Fool

Pathos AI Raises $237M at $3B Valuation in Round Led by Bristol Myers Squibb - citybiz

3 High-Yield Stocks to Buy With $1,000 Right Now - The Motley Fool

Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings? - The Motley Fool

Ähnlich wie BMY

GILD$170.683.06%

BIIB$253.621.59%